These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 30615982)

  • 1. Synergistic Cytotoxic Effect of Busulfan and the PARP Inhibitor Veliparib in Myeloproliferative Neoplasms.
    Patel PR; Senyuk V; Rodriguez NS; Oh AL; Bonetti E; Mahmud D; Barosi G; Mahmud N; Rondelli D
    Biol Blood Marrow Transplant; 2019 May; 25(5):855-860. PubMed ID: 30615982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
    Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
    J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms.
    Nieborowska-Skorska M; Maifrede S; Dasgupta Y; Sullivan K; Flis S; Le BV; Solecka M; Belyaeva EA; Kubovcakova L; Nawrocki M; Kirschner M; Zhao H; Prchal JT; Piwocka K; Moliterno AR; Wasik M; Koschmieder S; Green TR; Skoda RC; Skorski T
    Blood; 2017 Dec; 130(26):2848-2859. PubMed ID: 29042365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms.
    Pratz KW; Koh BD; Patel AG; Flatten KS; Poh W; Herman JG; Dilley R; Harrell MI; Smith BD; Karp JE; Swisher EM; McDevitt MA; Kaufmann SH
    Clin Cancer Res; 2016 Aug; 22(15):3894-902. PubMed ID: 26979391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.
    Owonikoko TK; Zhang G; Deng X; Rossi MR; Switchenko JM; Doho GH; Chen Z; Kim S; Strychor S; Christner SM; Beumer J; Li C; Yue P; Chen A; Sica GL; Ramalingam SS; Kowalski J; Khuri FR; Sun SY
    Cancer Med; 2014 Dec; 3(6):1579-94. PubMed ID: 25124282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells.
    Yin L; Liu Y; Peng Y; Peng Y; Yu X; Gao Y; Yuan B; Zhu Q; Cao T; He L; Gong Z; Sun L; Fan X; Li X
    J Exp Clin Cancer Res; 2018 Jul; 37(1):153. PubMed ID: 30012171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia.
    Pratz KW; Rudek MA; Gojo I; Litzow MR; McDevitt MA; Ji J; Karnitz LM; Herman JG; Kinders RJ; Smith BD; Gore SD; Carraway HE; Showel MM; Gladstone DE; Levis MJ; Tsai HL; Rosner G; Chen A; Kaufmann SH; Karp JE
    Clin Cancer Res; 2017 Feb; 23(4):899-907. PubMed ID: 27551000
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.
    LoRusso PM; Li J; Burger A; Heilbrun LK; Sausville EA; Boerner SA; Smith D; Pilat MJ; Zhang J; Tolaney SM; Cleary JM; Chen AP; Rubinstein L; Boerner JL; Bowditch A; Cai D; Bell T; Wolanski A; Marrero AM; Zhang Y; Ji J; Ferry-Galow K; Kinders RJ; Parchment RE; Shapiro GI
    Clin Cancer Res; 2016 Jul; 22(13):3227-37. PubMed ID: 26842236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.
    Murai J; Zhang Y; Morris J; Ji J; Takeda S; Doroshow JH; Pommier Y
    J Pharmacol Exp Ther; 2014 Jun; 349(3):408-16. PubMed ID: 24650937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
    Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
    Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and Evaluation of a Mitochondria-Targeting Poly(ADP-ribose) Polymerase-1 Inhibitor.
    Krainz T; Lamade AM; Du L; Maskrey TS; Calderon MJ; Watkins SC; Epperly MW; Greenberger JS; Bayır H; Wipf P; Clark RSB
    ACS Chem Biol; 2018 Oct; 13(10):2868-2879. PubMed ID: 30184433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.
    Gojo I; Beumer JH; Pratz KW; McDevitt MA; Baer MR; Blackford AL; Smith BD; Gore SD; Carraway HE; Showel MM; Levis MJ; Dezern AE; Gladstone DE; Ji JJ; Wang L; Kinders RJ; Pouquet M; Ali-Walbi I; Rudek MA; Poh W; Herman JG; Karnitz LM; Kaufmann SH; Chen A; Karp JE
    Clin Cancer Res; 2017 Feb; 23(3):697-706. PubMed ID: 27503200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2
    Fenerich BA; Fernandes JC; Rodrigues Alves APN; Coelho-Silva JL; Scopim-Ribeiro R; Scheucher PS; Eide CA; Tognon CE; Druker BJ; Rego EM; Machado-Neto JA; Traina F
    Signal Transduct Target Ther; 2020 Jan; 5(1):5. PubMed ID: 32296029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms.
    Bartalucci N; Tozzi L; Bogani C; Martinelli S; Rotunno G; Villeval JL; Vannucchi AM
    J Cell Mol Med; 2013 Nov; 17(11):1385-96. PubMed ID: 24237791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms.
    Hao X; Xing W; Yuan J; Wang Y; Bai J; Bai J; Zhou Y
    Invest New Drugs; 2020 Jun; 38(3):610-620. PubMed ID: 31227936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.
    Nguyen D; Zajac-Kaye M; Rubinstein L; Voeller D; Tomaszewski JE; Kummar S; Chen AP; Pommier Y; Doroshow JH; Yang SX
    Cell Cycle; 2011 Dec; 10(23):4074-82. PubMed ID: 22101337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP Inhibition Synergizes with Melphalan but Does not Reverse Resistance Completely.
    Patel PR; Senyuk V; Sweiss K; Calip GS; Pan D; Rodriguez N; Oh A; Mahmud N; Rondelli D
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1273-1279. PubMed ID: 32194286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.
    Valdez BC; Li Y; Murray D; Liu Y; Nieto Y; Champlin RE; Andersson BS
    Leuk Lymphoma; 2017 Nov; 58(11):2705-2716. PubMed ID: 28394191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
    Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
    Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic lethality between PARP-trapping and alantolactone-induced oxidative DNA damage in homologous recombination-proficient cancer cells.
    Wang H; Zhang S; Song L; Qu M; Zou Z
    Oncogene; 2020 Apr; 39(14):2905-2920. PubMed ID: 32029902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.